Nakao K. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 297: E1339 -E1348, 2009. First published October 6, 2009 doi:10.1152/ajpendo.00272.2009.-Ctype natriuretic peptide (CNP) plays a critical role in endochondral ossification through guanylyl cyclase-B (GC-B), a natriuretic peptide receptor subtype. Cartilage-specific overexpression of CNP enhances skeletal growth and rescues the dwarfism in a transgenic achondroplasia model with constitutive active mutation of fibroblast growth factor receptor-3. For future clinical application, the efficacy of CNP administration on skeletal growth must be evaluated. Due to the high clearance of CNP, maintaining a high concentration is technically difficult. However, to model high blood CNP concentration, we established a liver-targeted CNP-overexpressing transgenic mouse (SAP-CNP tgm). SAP-CNP tgm exhibited skeletal overgrowth in proportion to the blood CNP concentration and revealed phenotypes of systemic stimulation of cartilage bones, including limbs, paws, costal bones, spine, and skull. Furthermore, in SAP-CNP tgm, the size of the foramen magnum, the insufficient formation of which results in cervico-medullary compression in achondroplasia, also showed significant increase. CNP primarily activates GC-B, but under high concentrations it cross-reacts with guanylyl cyclase-A (GC-A), a natriuretic peptide receptor subtype of atrial natriuretic peptides (ANP) and brain natriuretic peptides (BNP). Although activation of GC-A could alter cardiovascular homeostasis, leading to hypotension and heart weight reduction, the skeletal overgrowth phenotype in the line of SAP-CNP tgm with mild overexpression of CNP did not accompany decrease of systolic blood pressure or heart weight. These results suggest that CNP administration stimulates skeletal growth without adverse cardiovascular effect, and thus CNP could be a promising remedy targeting achondroplasia. blood level elevation THE SKELETON OF A VERTEBRATE is formed by two different processes of ossification, membranous and endochondral. Most of the craniofacial bones are developed through membranous ossification (desmocranium). On the other hand, endochondral ossification leads to the development of vertebrae, long bones, and base of skull (chondrocranium) by the sequential formation and degradation of cartilaginous structure growth plates. It has been reported that many factors are implicated in the regulation of endochondral ossification, and mutations of these factors often cause skeletal dysplasias (10, 18, 35) .
blood level elevation THE SKELETON OF A VERTEBRATE is formed by two different processes of ossification, membranous and endochondral. Most of the craniofacial bones are developed through membranous ossification (desmocranium). On the other hand, endochondral ossification leads to the development of vertebrae, long bones, and base of skull (chondrocranium) by the sequential formation and degradation of cartilaginous structure growth plates. It has been reported that many factors are implicated in the regulation of endochondral ossification, and mutations of these factors often cause skeletal dysplasias (10, 18, 35) .
Achondroplasia is the most common form of human dwarfism, and it results from a constitutively active mutation in the gene encoding fibroblast growth factor receptor-3, which is a strong negative regulator of endochondral ossification via suppression of proliferation and differentiation of growth plate chondrocytes (1, 32) . Currently, distraction osteogenesis, an orthopedic procedure, is applied to limbs of achondroplasia patients. The procedure improves height, but it does not recover any of the other symptoms related to achondroplasia, such as midface deficiency, short fingers, spinal stenosis, and cervico-medullary compression (CMC) (1, 6) . Moreover, this procedure imposes heavy burdens on the patient, such as having to wear an external fixator, or complications, including microbial infections (34) . Growth hormone treatment seems to have only modest short-term success and lacks long-term benefits. Furthermore, the treatment may cause growth hormone-related metabolic adverse effects by affecting lipid profiles and muscle mass (14) .
The natriuretic peptide family consists of three structurally related peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The biological actions of the natriuretic peptides are mediated by two types of membrane-bound receptors, guanylyl cyclase-A (GC-A) for ANP and BNP and guanylyl cyclase-B (GC-B) for CNP (17, 22, 24, 30) . These receptors are linked to the cyclic guanosine monophosphate-dependent signaling cascade. ANP and BNP are produced mainly in the atrium and ventricle, respectively, and are thought to be implicated in cardiovascular homeostasis through GC-A. On the other hand, CNP is produced in a wide variety of tissues, where it acts locally as an autocrine/paracrine factor through GC-B. It has been reported that the CNP/GC-B system is involved in endochondral ossification. Inactivation of the CNP/GC-B pathway in mice by depletion of CNP (5), GC-B (29) , or cyclic guanosine monophosphate-dependent protein kinase II (21) , a downstream mediator of the CNP/GC-B system, results in dwarfism caused by impaired endochondral ossification. By contrast, activation of GC-B in transgenic mice with highly elevated blood BNP concentrations (26) or in mice with depletion of the clearance receptor for natriuretic peptides (13) leads to skeletal overgrowth. In humans, loss-of-function mutations in GC-B cause autosomal recessive skeletal dysplasia, acromesomelic dysplasia, type Maroteaux (2) . These results strongly suggest that GC-B activation is one of the major positive regulators of endochondral ossification.
Local overexpression of CNP in chondrocytes stimulated endochondral ossification and rescued the dwarfism of the achondroplasia model mouse with mutated constitutive active fibroblast growth factor receptor-3 (33) . These results provide a scientific rationale for the clinical application of CNP for achondroplasia. In contrast to ANP and BNP, CNP is currently thought to be a local regulator and to exert its biological actions in an autocrine/paracrine manner (7, 27) . Therefore, any endocrine-like effect of CNP on endochondral bone growth must be examined before clinical application. It has been reported that CNP is rapidly metabolized by neutral endopeptidase (NEP) and cleared by a clearance receptor (4) and has a very short half-life (2.6 min) in humans (9) . These suggest a low bioavailability and will hamper examination of the effects of CNP administration on endochondral ossification. Additionally, CNP primarily activates GC-B, but it could cross-react with GC-A at high concentrations (27) . Excess activation of GC-A could cause hypotension and heart weight reduction (25) . Therefore, we must also examine whether stimulation of endochondral ossification due to chronically elevated plasma CNP levels can occur independently from cardiovascular effects.
To examine these issues, we generated transgenic mice with chronically elevated plasma CNP levels from liver-specific CNP overexpression, using a human serum amyloid P (SAP) promoter [SAP-CNP transgenic mice (tgm)] (36). Here, we report the phenotypes of SAP-CNP tgm, which show stimulation of endochondral ossification without apparent cardiovascular effects due to CNP overexpression in liver.
MATERIALS AND METHODS

Generation of CNP transgenic mice.
A transgene was designed to express CNP specifically in the liver under control of the human SAP component promoter (36) . The coding sequence fragment of mouse CNP was inserted into the blunt-ended EcoRI sites of the pSG2 vector, which resulted in the SAP-CNP fusion gene. The HindIII-XbaI fragment of the SAP-CNP fusion gene was purified and microinjected into the pronucleus of C57BL/6J embryos using standard techniques. Founders were identified by Southern blot analysis and mated with C57 BL/6J mice (CLEA Japan, Tokyo, Japan) to establish lines. We established two lines of transgenic mice, lines 17 and 40, with similar skeletal phenotypes, and these phenotypes were milder in line 17 than in line 40. The heterozygosity of the transgenic mice was maintained. Animals were housed at 22-26°C in a 12:12-h light-dark cycle with access to standard rodent chow CE-2 (CLEA Japan) and tap water ad libitum. After animals reached 3 wk of age, body weight and body length as the naso-anal length were measured every week. The Institutional Animal Care and Use Committee of Chugai Pharmaceutical reviewed the protocols and confirmed that the animals used in this study were cared for and used under the Guiding Principles for the Care and Use of Research Animals promulgated by Chugai Pharmaceutical.
Analysis of transgene expression. The transgene expression in cartilage, muscle, kidney, heart, lung, brain, intestine, and liver was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was prepared from mouse tissues using Isogen (Nippon Gene, Tokyo, Japan), and cDNA was synthesized with ReverTra Ace (Toyobo, Osaka, Japan). PCR was performed using Taq polymerase (Takara Bio, Otsu, Japan). All procedures were carried out according to the manufacturers' instructions. To detect the transgene expression distinguished specifically from endogenous CNP expression, the untranslated sequence of pSG2 vector and the mouse CNP cDNA sequence were used as the forward primer and reverse primer, respectively (forward: 5Ј-GCTGGTTGTTGTGCTGTCTC-3Ј; reverse: 5Ј-CCGATCCGGTCCAGCTTGAG-3Ј; product, 427 bp).
Internal control RT-PCR was performed with ␤-actin (forward: 5Ј-GCCATGGATGACGATATCGCT-3Ј; reverse: 5Ј-CGCCTAGAAG-CACTTGCGGTG-3Ј; product, 1,134 bp).
Measurement of blood CNP concentration. Blood CNP concentration was measured using RIA kits (CNP-22 RIA and CNP-22 ultrasensitive RIA kits; Phoenix Pharmaceuticals, Belmont, CA) according to the manufacturer's instructions. For the RIA assays, blood withdrawal tubes contained 1 mg of EDTA-4Na (Junsei Chemical, Tokyo, Japan) for 1 ml of blood and were stored on ice immediately. Aprotinin was added (0.6 TIU/ml; Sigma, St. Louis, MO) and mixed to inhibit proteinase activity. Plasma was separated by centrifugation (3,000 rpm, 4°C, 20 min) and stored at Ϫ80°C until use. CNP extraction was carried out according to the manufacturer's recommendation using C18 sep-column (Nihon Waters, Tokyo, Japan), 1% trifluoroacetic acid (Wako Pure Chemical industries, Osaka, Japan), and 60% acetonitrile (Junsei Chemical) in 1% trifluoroacetic acid.
Quantitative real-time RT-PCR. The expression of natriuretic peptide receptor-C (NPR-C) mRNA in heart and costal cartilage was analyzed by quantitative real-time PCR. Heart and costal cartilage (including growth plate) were quickly removed from wild-type littermates and transgenic mice of SAP-CNP tgm line 17 (8 -10 wk old, male; n ϭ 4 each) and quickly frozen in liquid nitrogen. Total RNA was extracted using Isogen (Nippon Gene) and then purified using RNeasy Mini Kit (Qiagen, Tokyo, Japan).
TaqMan Gene Expression Assays for NPR-C (cat. no. Mm00435329_ m1) and GAPDH (Mm99999915_g1) were purchased from Applied Biosystems (Foster City, CA). The expression levels of each mRNA were quantified in duplicate using Applied Biosystems 7900HT RealTime PCR System according to the manufacturer's protocol. The arbitrary value for NPR-C was normalized to that of GAPDH, and then relative values from costal cartilage of wild-type littermates were calculated.
Radiography. To examine the morphological skeletal phenotypes of SAP-CNP tgm, radiography was carried out using a FX-1000 system (25 kV, 80 mA, 6 s; Fujifilm, Tokyo, Japan). Image analysis was performed by an imaging analyzer (BAS-5000; Fujifilm).
Bone mineral density. Bone mineral density of femur and lumbar spine (L 2-4) was measured by dual-energy X-ray absorptiometry (DCS-600EX; Aloka, Tokyo, Japan).
Proteoglycan synthesis in growth plates. Proteoglycan synthesis in growth plates were assessed using ex vivo cultures of costal growth plates by measuring the incorporation of [ 35 S]sulfate, as described previously (33) . In brief, the costal growth plates were isolated from the third, fourth, and fifth ribs of 5-wk-old mice. Under a microscope, soft tissues were carefully removed from the ribs, and the growth plates were separated from the costal bones. Subsequently, the growth plates were cultured in Dulbecco's modified Eagle's medium (Invitrogen Japan, Tokyo, Japan) supplemented with 10% fetal bovine serum (HyClone, South Logan, UT), antibiotics (Invitrogen Japan), and 1.1 MBq/ml [ 35 S]sulfate (PerkinElmer Japan, Yokohama, Japan) at 37°C for 3 h. The growth plates were then rinsed three times with PBS solution and digested with papain (Sigma) at 60°C for 16 h. The digested sample was added to the precipitation solution for glycosaminoglycans [0.3% cetylpyridinium chloride (Sigma), 3 g/ml chondroitin sulfate C (Wako Pure Chemical Industries), 0.7 mmol/l MgSO4 (Nacalai Tesque, Kyoto, Japan), 70 mmol/l Tris ⅐ HCl (pH 7.8; Sigma), 1.5 mmol/l CaCl2 (Nacalai Tesque)]. The precipitate was captured on a glass filter (Advantec, Tokyo, Japan) and washed three times with 1% cetylpyridinium chloride in 20 mmol/l NaCl (Wako Pure Chemical Industries). The radioactivity of the precipitate was measured by a liquid scintillation analyzer (Packard TR-2700; PerkinElmer, Wellesley, MA). Bone morphometry was performed using a caliper (Mitutoyo, Tokyo, Japan).
Histological analysis. The hindlimbs were fixed in 20% formalin neutral buffered solution (pH 7.4; Wako Pure Chemical Industries) and decalcified in 20% EDTA (pH 7.4; Junsei Chemical). Decalcified tissues were embedded in paraffin. Four-micrometer-thick sections were stained with hematoxylin and eosin (H & E; Sakura Finetek Japan, Tokyo, Japan). To detect sulfated proteoglycans, safranin O (Merck, Darmstadt, Germany) staining was carried out using standard procedures.
For immunohistochemistry, sections were stained using the following antibodies. Primary antibodies included rabbit anti-type II collagen antibody (LSL, Tokyo, Japan), rabbit anti-type X collagen antibody (LSL), goat anti-Runx2 (Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-parathyroid hormone (PTH)/PTH-related peptide receptor (PTH1R; Santa Cruz Biotechnology), goat anti-Ihh (Indian hedgehog; Santa Cruz Biotechnology), and rabbit anti-PCNA antibody (Santa Cruz Biotechnology). Secondary antibodies included biotinylated anti-rabbit IgG (Vector Laboratories) and biotinylated anti-goat IgG (Vector Laboratories). Immunoreaction signals were detected using a Dako LSAB2 kit (Dako, Copenhagen, Denmark). To confirm antibody specificity, rabbit preimmune serum (LSL), rabbit preimmune IgG fraction (Santa Cruz Biotechnology), or preimmune goat IgG fraction (Vector Laboratories) was used as the first antibody negative control.
Morphometric analyses were performed using software (IPAP; Sumika Technoservice, Hyogo, Japan) connected to a light microscope (Olympus, Tokyo, Japan). The thickness of resting, proliferating, and hypertrophic layers of the tibial growth plate was calculated as the mean thickness of five different ϫ10 objective lens fields in the H & E-stained specimens. Total thickness of growth plate was calculated as the sum of the three zones above. The cellularity of chondrocytes in the tibial growth plate was calculated as the mean chondrocyte number/field in five different ϫ10 objective lens fields of the H & E-stained specimens. The proportion of proliferating chondrocytes was calculated as the frequency of PCNA-positive cells using the following formula: PCNA positive cell percentile (%) ϭ PCNA-positive cell no./200 chondrocytes ϫ 100.
Measurement of systolic blood pressure. Systolic blood pressure (SBP) was measured in conscious animals using the tail-cuff method (BP-98A; Softron, Tokyo, Japan).
Heart weight. Under anesthesia by inhalation of 3% isoflurane, mice were euthanized by exsanguination from the ventral vein. The heart was excised and weighed using an electric balance (EB-50; Shimadzu, Kyoto, Japan). Relative heart weight was calculated by the following formula: relative heart weight (%) ϭ heart weight (g)/body weight (g) ϫ 100.
Statistical analysis. The statistical significance was determined by Student's t-test using SAS statistical software (SAS Institute, Tokyo, Japan). Values of P Ͻ 0.05 were considered statistically significant vs. control (P Ͻ 0.05, P Ͻ 0.01).
RESULTS
Generation of SAP-CNP tgm.
To examine the effect of elevated blood CNP concentration on endochondral ossification, we generated the SAP-CNP tgm, a model with liverspecific CNP overexpressed under the control of a liverspecific SAP promoter (Fig. 1A) . We obtained two lines of SAP-CNP tgm, lines 17 and 40 (Fig. 1B) .
Blood CNP levels. We measured plasma CNP concentrations using two RIA kits with different sensitivities to CNP (standard: CNP-22, linear range of 10 -80 pg/ml; ultrasensitive: CNP-22, linear range of 2.5-40 pg/ml). In line 40, the blood CNP level in the wild type (n ϭ 5) was very low, less than the detection limit (10 pg/ml) of the standard RIA kit. In contrast, the blood CNP level in SAP-CNP tgm was very high at 23.7 Ϯ 15.8 ng/ml (means Ϯ SD; n ϭ 4). SAP-CNP tgm had blood CNP levels Ն2,300 times higher than wild-type littermates. The retrieval rate of CNP-22 in column C18 was 83%.
In contrast, in line 17, differences in blood CNP levels of SAP-CNP tgm and wild-type littermates were not detected by the standard RIA kit. Therefore, we used the ultrasensitive CNP RIA kit to analyze line 17. The transgene of SAP-CNP tgm contains the cDNA sequence of mouse prepro-CNP, and presumably, various molecular forms of CNP, including CNP-53 and CNP-22, are expressed in SAP-CNP tgm. With this in mind, we investigated the sensitivity of the ultrasensitive RIA kit to CNP-22 and CNP-53 prior to analysis of the blood CNP levels in SAP-CNP tgm line 17. The sensitivity of the ultrasensitive RIA kit to CNP-53 was approximately onethird that of CNP-22 (data not shown), indicating that both CNP-22 and CNP-53 can be detected by this RIA kit with different sensitivities to respective CNP molecular forms. The retrieval rate in column C18 was 93% for CNP-22 and 83% for CNP-53 with the ultrasensitive RIA kit. In this assay system, SAP-CNP tgm revealed an 84% higher blood CNP level (7.5 Ϯ Fig. 1 . Generation of serum amyloid P-C-type natriuretic peptide transgenic mouse (SAP-CNP tgm). A: schematic representation of the SAP-CNP transgene. P, PvuII. B: Southern blot analysis of the transgene. TG, SAP-CNP transgenic mouse; WT, wild-type littermate. Tail genomic DNA (15 g) was digested with PvuII (200 U). Transgene (2.0 kbp) was detected only in TG, whereas the band for wild-type allele (2.4 kbp) was detected both in WT and TG. C: expression of the transgene. Expression of the transgene was examined in cartilage, muscle, kidney, heart, lung, brain, small intestine, and liver by RT-PCR. Only liver expressed the transgene mRNA.
2.5 pg/ml, means Ϯ SD; n ϭ 8, P ϭ 0.002) than that of the wild-type littermate (4.1 Ϯ 0.5 pg/ml, means Ϯ SD; n ϭ 8).
Taken together, these results demonstrated that SAP-CNP tgm line 40 is an extremely overexpressing line and line 17 is a mildly overexpressing line.
Cardiovascular phenotypes of SAP-CNP tgm. SAP-CNP tgm line 17 showed no significant difference in SBP levels compared with wild-type littermates. On the other hand, the SBP in line 40 with highly elevated blood CNP concentrations was significantly lower (ϳ23%) than that of wild-type littermates (Table 1) . Heart weight measurements for line 17 were not different from those of wild-type littermates. In contrast, line 40 revealed a significant decrease in heart weight compared with wild-type littermates ( Table 2) .
Expression of the transgene. Because the skeletal overgrowth in SAP-CNP tgm line 17 was not accompanied with cardiovascular alterations, we hypothesized that line 17 could be a suitable model to examine the effects of CNP on skeletal system in an endocrine manner. We examined the transgene expression in various organs (liver, skeletal muscle, kidney, heart, lung, brain, small intestine, and costal cartilage) in line 17 using RT-PCR. Liver-specific expression of the transgene was observed in SAP-CNP tgm but not in wild-type littermates (Fig. 1C) . This demonstrated that SAP-CNP tgm line 17 is a suitable model for the elucidation of the effect of chronically elevated plasma CNP levels in mouse concerning effects other than that related to the cardiovascular system. Therefore, we examined the phenotypes of SAP-CNP tgm line 17.
Expression of NPR-C in heart and costal cartilage. To estimate local availability of CNP in heart and cartilage in SAP-CNP tgm line 17, mRNA expression of NPR-C clearance receptor was compared between wild-type littermates and transgenic mice by real-time PCR. As a result, an ϳ53% increase in NPR-C mRNA expression was observed in the heart of transgenic mouse. In contrast, a 42% decrease of NPR-C mRNA expression was observed in costal cartilage of transgenic mouse (Fig. 2) .
Growth of SAP-CNP tgm. SAP-CNP tgm exhibited systemic elongation of cartilage bones such as limb, paw, and spine (Fig. 3A) . During postweaning development, increased body length was observed in proportion to plasma CNP level in both lines 17 and 40. In line 17, elongation of the body was apparent at 5 wk of age. In line 40, skeletal overgrowth was first detected at 3 wk of age (Fig. 3B) . Transgenic mice in both lines became progressively hump-backed due to excessively elongated spines. This phenotype was revealed more apparently in line 40 than in line 17. There was no significant difference in body weights at any age among the SAP-CNP tgm line 17, line 40, and wild-type littermates (Fig. 3C) .
Skeletal phenotypes of SAP-CNP tgm. We examined the skeletal phenotypes of SAP-CNP tgm line 17 in detail. Radiographs showed systemic elongation of cartilage bones (humerus, femur, tibia, paw, spine, and skull) in line 17 compared with those in wild-type littermates (Fig. 4) . No gross skeletal defects were observed in SAP-CNP tgm line 17 ( Fig. 4A) .
At the age of 10 wk, the lengths of the lumbar (L 2-4 ) and femur in SAP-CNP tgm line 17 were 6 and 13% larger, respectively, than that of wild-type littermates (Fig. 5, A and  B) . Skull growth was also stimulated in SAP-CNP tgm (lengths are given in Fig. 5C ; widths were wild type: 12.2 Ϯ 0.3 mm, and SAP-CNP tgm: 12.7 Ϯ 0.3 mm, P Ͻ 0.01). Width of the foramen magnum in SAP-CNP tgm was significantly dilated (Fig. 5D) .
Bone mineral density was measured in the femur and lumbar spine (L 2-4 ) in males and females in line 17 at 9 wk of age. Although both femur (wild type: 28.9 Ϯ 0.7 mg/cm 2 , SAP-CNP tgm: 25.6 Ϯ 0.6 mg/cm 2 , means Ϯ SD; n ϭ 7, female) and spine (wild type: 29.0 Ϯ 1.1 mg/cm 2 , SAP-CNP tgm: 26.3 Ϯ 0.6 mg/cm 2 , means Ϯ SD; n ϭ 7, female) bone mineral Fig. 2 . Expression of natriuretic peptide receptor-C (NPR-C) mRNA in heart and costal cartilage in SAP-CNP tgm line 17. Relative NPR-C mRNA expression was standardized with GAPDH mRNA expression in individual samples. The mean values in each organ were standardized with the mean value of costal cartilage in the wild-type (wild) littermates. In heart, transgenic mice (tgm) showed 53% increased expression of NPR-C mRNA compared with that of wild littermates. In contrast, tgm showed 42% decreased expression in costal cartilage. Means ϩ SE; n ϭ 4. Histological examinations. Histomorphometric analysis of tibial growth plates from 10-wk-old mice showed that SAP-CNP tgm line 17 had 47% thicker growth plates than that of wild-type littermates (SAP-CNP tgm : 221.4 Ϯ 6.3 m, wild type: 150.2 Ϯ 4.7 m, means Ϯ SE; n ϭ 7 each, P Ͻ 0.01; Fig. 6, A  and B) . Columnar alignment of chondrocytes was maintained in Both lines revealed continuous skeletal overgrowth during the examined age periods. Means Ϯ SD; n ϭ 8. *P Ͻ 0.05, **P Ͻ 0.01 vs. wild type. Student's t-test. C: course of the body weights in male SAP-CNP tgm lines 17 and 40 and wild-type littermates. Within the observed ages, there were no significant differences among the 3 genotypes during examined age periods. Means Ϯ SD; n ϭ 8. (Fig. 6A) . The width of resting, proliferating, and hypertrophic layers of growth plates was increased significantly in SAP-CNP tgm (Fig. 6B) , but there was no difference in the cellularity in the individual zones of growth plates between SAP-CNP tgm and wild-type littermates (Fig. 6C) . There was also no apparent alteration in chondrocyte morphology in the resting, proliferating, and hypertrophic zones in SAP-CNP tgm compared with wild-type littermates (Fig. 6A) . Although the proportion of PCNA-positive chondrocytes in proliferating layer of growth plate tended to be lower in line 17 than in wild-type littermates, it was not significant (Fig. 6D) .
SAP-CNP tgm
We examined other cartilage tissue, including auricle, trachea, intervertebral disk, and meniscus, in SAP-CNP tgm and found that no significant histological change was observed (data not shown). Furthermore, no significant histopathological findings were observed in any major organs, including liver, spleen, kidney, heart, lung, brain, and alimentary tract (data not shown).
Immunohistochemistry for chondrocyte differentiation marker proteins. To examine the chondrocytic differentiation in the growth plate of SAP-CNP tgm line 17, we analyzed the expression of chondrocyte differentiation marker proteins, including type II collagen, type X collagen, PTH1R, Ihh, and Runx2 (Cbfa1), by immunohistochemistry (Fig. 7) . The expression of type II collagen was detected in a diffuse pattern in the matrix of growth plate cartilage. Type X collagen was detected specifically in the cartilage matrix of prehypertrophic and hypertrophic zones. The collagens were stained in similar patterns in SAP-CNP tgm and wild-type littermates (Fig. 7 , C-F, and Table 3 ). The other molecular markers of chondrocyte differentiation (PTH1R, Ihh, and Runx2) were expressed in prehypertrophic to hypertrophic chondrocytes in similar patterns in both SAP-CNP tgm and wild-type littermates (Fig.  7 , G-L, and Table 3 ). We did not find any differences between the staining patterns of the chondrocyte differentiation markers of SAP-CNP tgm and wild-type littermates.
DISCUSSION
The critical role of CNP/GC-B axis in endochondral ossification has been reported in mouse and human (2, 5, 29) . Reflecting the role of CNP, the efficacy of CNP for achondroplasia is suggested in cartilage-targeted CNP-overexpressing transgenic mouse (33) .
However, since CNP physiologically acts in an autocrine/ paracrine manner (27) , its effect on endochondral bone growth in an endocrine manner must be evaluated for clinical application. On the other hand, because the clearance of CNP in vivo is high (9) , it is expected to be difficult keeping plasma CNP levels chronically high. Therefore, to examine the effects of chronically elevated plasma CNP levels on endochondral ossification, we generated a transgenic mouse (SAP-CNP tgm) with targeted overexpression of CNP in liver under control of a liver-specific promoter (19) .
We established two lines of SAP-CNP tgm (line 17 and line 40) with different plasma CNP levels. The plasma CNP levels of line 17 and line 40 were significantly higher than that of wild-type littermates (line 17: 1.8-fold; line 40: Ͼ2,300-fold). Both SAP-CNP tgm lines exhibited skeletal overgrowth in proportion to plasma CNP level. Although CNP reacts selectively with GC-B under physiological concentrations, it also activates GC-A in very high concentrations (28) . Since the ANP transgenic mouse showed hypotension and heart weight decrease (25), we examined blood pressure and heart weight in lines 17 and 40 of SAP-CNP tgm. The results for line 40 showed hypotension and heart weight decrease. In contrast, line 17 exhibited no alterations in blood pressure or heart weight. These data suggest that both GC-A and GC-B were activated in line 40, and GC-B was specifically activated in line 17. It was reported that the rank order of GC-A activation and GC-B activation by natriuretic peptides is ANP Ն BNP ϾϾ CNP and CNP ϾϾ ANP Ն BNP, respectively (28) . It is thought that this selectivity between ligands and receptors provides the primary effect of CNP on skeletal growth via GC-B. On the other hand, involvement of GC-B in hypotensive effect of CNP is reported in GC-A-knockout mouse (11) . This result does not coincide with the phenotype of line 17 transgenic mice, which shows skeletal overgrowth without cardiovascular change. One of the possible explanations of this discrepancy is that lack of cardiovascular effects with mild elevation of plasma CNP levels can reflect only an insufficient concentration of CNP to induce cardiovascular effects. As for another possible explanation, different local CNP availability between cardiovascular system and skeletal system will be raised. Our observation of increased expression of NPR-C mRNA in heart and decreased expression in cartilage will support this hypothesis. Although NEP is also involved in the clearance of CNP (31), it is reported that NEP-knockout mice show no apparent change in their appearance (12) , in contrast to the skeletal overgrowth phenotype of NPR-C-knockout mice (13) . These reports might suggest that contribution of NEP to local availability of CNP in endochondral ossification is lower than that of NPR-C. Further precise examinations should be carried out to clarify CNP signaling in line 17. Fig. 7 . Immunohistochemistry in tibial growth plate. Safranin O staining for sulphated proteoglycan was carried out to identify growth plate (A and B) . The cartilage matrix of SAP-CNP tgm line 17 (B) revealed slightly thicker staining with Safranin O than that of wild-type littermates (A). Type II collagen (Col II) was diffusely detected in the growth plate of both wild-type (C) and SAP-CNP tgm line 17 mice (D). Type X collagen (Col X) was detected mainly in the hypertrophic zone of both wild-type (E) and SAP-CNP tgm mice (F). Parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R; G and H) and Indian hedgehog (Ihh; I and J) were detected in the proliferating layer (faintly positive), the prehypertrophic zone (mildly positive), and the hypertrophic zone (apparently positive). Runx2 (K and L) was detected in the prehypertrohic (mildly positive) and hypertrophic (apparently positive) zones. PTH1R, Ihh, and Runx2 were detected in similar patterns in both wild-type and SAP-CNP tgm line 17 mice. Negative control antibodies for the individual primary antibodies showed no specific staining (data not shown). Bar, 100 m. 
Col II, collagen type II; Col X, collagen type X; PTH1R, parathyroid hormone/parathyroid hormone-related peptide receptor; Ihh, Indian hedgehog. There was no apparent difference in the staining patterns and intensity between SAP-CNP tgm and wild-type littermates. Ϫ, No staining; Ϯ, faintly positive; ϩ, mildly positive; ϩϩ, apparently positive; ϩϩϩ, markedly positive.
Recently, skeletal overgrowth in a human example of CNP overexpression with t(2; 7) chromosomal translocation was reported (3). The plasma CNP level of the case is approximately twofold higher than that of normal subjects. SAP-CNP tgm line 17 might have similar phenotypes to that of the reported human case.
Body lengths of SAP-CNP tgm were significantly longer than those of wild-type littermates throughout the period of observation. However, body weights were not significantly different between SAP-CNP tgm and wild type. Also, BNP transgenic mice exhibit skeletal overgrowth via activating GC-B without body weight change (26) . Since there is a tendency to decrease abdominal adipose tissue in lines 17 and 40 (data not shown), lipolytic effect of CNP (23) might occur in SAP-CNP tgm. On the other hand, a growth hormone transgenic mouse reveals that phenotypes of skeletal overgrowth and body weight increase (20) . Compared with growth hormones, chronically elevated plasma CNP levels might affect the skeletal growth and adipogenesis in a different mode of action. Further examinations for this issue should be carried out in the future.
Endochondral ossification was systemically stimulated in the SAP-CNP tgm. The femur, skull, and spine (L 2-4 ) measurements were longer than that of the wild-type littermates, suggesting that chronically elevated plasma CNP levels stimulate cartilage bones systemically. Stimulated proteoglycan synthesis in the costal growth plates of SAP-CNP tgm supports this hypothesis. In achondroplasia, midface deficiency and CMC are observed as the characteristic clinical signs (6, 32) . Elongation of skull and widening of foramen magnum in SAP-CNP tgm might suggest that CNP can overcome not only dwarfism but also the base of skull-related problems in achondroplasia.
There was a tendency of lower bone mineral density in femur and lumbar spine (L 2-4 ) of SAP-CNP tgm than of wild-type littermates. Since the quality of bone after CNP administration is an important issue in the clinical application of this peptide, it should be examined in detail.
According to the histological data, skeletal overgrowth in SAP-CNP tgm line 17 was accompanied with thickening of growth plates, suggesting that chronically elevated plasma CNP levels affected elongation of the endochondral bones. The thickened growth plates in SAP-CNP tgm line 17 maintained the same histological features of chondrocyte differentiation as the wild-type littermates. The thickness of resting, proliferating, and hypertrophic layers in the growth plates was higher in SAP-CNP tgm than that in wild type. The columnar alignment of chondrocytes was maintained in both SAP-CNP tgm and wild-type littermates. Both the cellularity and the PCNApositive percentile in growth plate chondrocytes of SAP-CNP tgm were similar to those of the wild-type littermates. These data coincide with that of cartilage-specific CNP-overexpressing transgenic mice (33) . On the other hand, it has been reported that CNP stimulates chondrocyte proliferation accompanied with increased cartilage matrix accumulation (16) . In this study, although proteoglycan synthesis in costal growth plate was stimulated significantly in SAP-CNP tgm, PCNA immunostaining did not suggest stimulation of chondrocyte proliferation. These discrepancies need to be clarified by further investigations to unveil the mode of action of CNP in endochondral ossification. SAP-CNP tgm (lines 17 and 40) did not exhibit apparent histological abnormality in cartilage tissues such as trachea, auricle, intervertebral disk, and meniscus (data not shown). This suggests that CNP selectively affects only cartilage relating to endochondral ossification.
Immunohistochemistry for chondrocyte differentiation marker proteins showed no apparent difference in staining patterns of the markers in tibial growth plates between SAP-CNP tgm and wild-type littermates. This suggests that normal chondrocytic differentiation was maintained in the growth plate of SAP-CNP tgm. Disorganized differentiation of growth plate chondrocytes in the cGMP-dependent protein kinase II-knockout mouse model, which lost one of the CNP/GC-B signaling pathways, was reported (15, 21) . Since no apparent difference in the expression patterns of markers for chondrocyte differentiation between SAP-CNP tgm and wild-type littermates was observed in this study, we think that continuous CNP/GC-B signaling might not alter the regulation of chondrocyte differentiation in the growth plate.
Using SAP-CNP tgm, we demonstrated that chronic elevation of plasma CNP levels systemically stimulates endochondral ossification. Our observations strongly suggest that CNP administration can be a novel and promising therapeutic strategy for achondroplasia to overcome dwarfism and other complications, including midface deficiency and CMC. Further investigations should be carried out, including evaluation of the efficacy of CNP in an animal model of achondroplasia, to establish a scientific rationale for future clinical application.
